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Abstract
Background—Stent thrombosis is a lethal complication of endovascular intervention. Concern
has been raised for the inherent risk associated with specific stent designs and drug-eluting
coatings, yet clinical and animal support are equivocal.
Methods and Results—We examined whether drug-eluting coatings are inherently
thrombogenic and if the response to these materials was determined to a greater degree by stent
design and deployment using custom-built stents. Drug/polymer coatings uniformly reduce rather
than increase thrombogenicity relative to matched bare-metal counterparts (0.65-fold, p=0.011).
Thick-strutted (162 μm) stents were 1.5-fold more thrombogenic than otherwise identical thin-
strutted (81 μm) devices in ex vivo flow loops (p<0.001), commensurate with 1.6-fold greater
thrombus coverage three days after implantation in porcine coronary arteries (p=0.004). When
bare-metal stents were deployed in malapposed or overlapping configurations, thrombogenicity
increased compared to apposed, length-matched controls (1.58-fold, p=0.001 and 2.32-fold,
p<0.001). The thrombogenicity of polymer-coated stents with thin struts was lowest in all
configurations and remained insensitive to incomplete deployment. Computational modeling-
based predictions of stent-induced flow derangements correlated with spatial distribution of
formed clots.
Conclusions—Contrary to popular conception drug/polymer coatings do not inherently increase
acute stent clotting – they reduce thrombosis. However, strut dimensions and positioning relative
to the vessel wall are critical factors in modulating stent thrombogenicity. Optimal stent
geometries and surfaces, as demonstrated with thin stent struts, help reduce the potential for
thrombosis despite complex stent configurations and variability in deployment.
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Introduction
Stent thrombosis (ST) is a potentially lethal complication of endovascular intervention that
arises early after implantation and can persist for years with drug-eluting stents (DES).
Steady state risk of ~ 0.6–1% annually1, 2 is increased by ubiquitous co-morbidities like
diabetes mellitus, renal failure, and congestive heart failure,3–6 and use in arterial
bifurcations, long lesions, or overlap.7–10 Stent-wall malapposition has been observed using
intravascular ultrasound (IVUS) in nearly 80% of cases presenting with ST.7 Importantly,
ST incidence increases substantially when multiple risk factors occur simultaneously,
exceeding 12% in some analyses.5
The issue of device and material biocompatibility is not unique to stents – it is a grander
issue and must be perceived as contextual rather than constitutive.11 Thus, stent geometry,
material, and coatings can affect thrombogenicity but it is incumbent upon us to define when
and how. Given stent position adjacent to the injured vessel wall and within the flowing
bloodstream, it is natural to consider the flow environment, vessel wall, and blood state as
contextual elements influencing ST.12, 13 We evaluated the thrombogenicity of bare and
polymer/drug-coated stents using an integrated approach employing ex vivo, in vivo and in
silico insights. Well-deployed conformations were compared with high-risk scenarios where
stent-induced flow disruptions arise from increased strut dimension, or device malapposition
or overlap.
Methods
Ex Vivo Flow Setup
A modified Chandler Loop evaluated endovascular device thrombosis.14 Motor-controlled
rotors accelerate blood-filled silicone loops (Figure 1a; 3.18 mm ID/4.76 mm OD, shore
50A durometer, 3350 Tygon), generating pulsatile flow simulating coronary-like
hemodynamics (peak flow 200ml/min).13, 14 To model wall injury, loop segments were
made reactive through 8 hour incubation with 28.3% Bovine Type-I collagen solution
(Beckton Dickinson) and subsequently rinsed with PBS, pH~7.4. Stents of different designs
were balloon-expanded into the reactive segments under specific deployment configurations
(well-apposed, malapposed, or overlapped). Blood was collected from naïve 4-month old
Yorkshire pigs (36–40kg) per institutional protocols (Concord Biomedical Sciences &
Emerging Technologies) in 10% acid-citrate-dextrose solution (ACD; 85mM trisodium
citrate, 69mM citric acid, 111mM glucose, pH~4.6). Prior to use, blood was repleted with a
100mM CaCl2/75mM MgCl2 solution with 62.5μL calcium/magnesium solution per 1mL of
blood. Loops were filled, rotor-mounted and run for 4 minutes allowing in-stent thrombus
formation. Free blood was emptied and reactive segments isolated and flushed with 120ml
Tyrode’s solution supplemented with HEPES buffer and magnesium (0.01M HEPES,
0.75mM MgCl2). After visual assessment (Figure 1a), stented segments were excised and
filled with 1% Triton-X solution for 20 minutes. Equi-volume lysates were collected and
lactate dehydrogenase (LDH) levels determined to provide quantitative measure of platelet/
cell adhesion reflecting thrombogenicity (CytoTox 96R Non-Radioactive Cytotoxicity
Assay, Promega Corporation).13, 14
Ex Vivo Comparisons of Basic Stent Design
ST was evaluated in well-deployed and high-risk scenarios where flow disruptions arise
from stent protrusion or device malapposition (Supplemental Material). Stents were pre-
mounted on balloon catheters (Abbott Vascular). Bare-metal thin-strut (81×81μm2) stents
with a platform identical to clinical MULTI-LINK VISION (MLV) stents were compared to
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custom-built non-clinical stents of identical design but two-fold thicker (“THICK-STRUT”
VISION; TSV 162×81μm2) struts (3.0×12mm; N=8 per group). Apposed DES formulated
on the thin MLV backbone (XIENCE V, XVS, 96×96μm2, 3.0×12mm) ran concurrently
(N=8) to examine the effect of drug/polymer coatings. A range of clinical-build BMS and
DES was also tested. 3.0×12mm BMS (MLV, Driver, TAXUS, Bx VELOCITY; N=6 each)
were inflated to 3.2mm and compared to similarly deployed, 3.0×12mm DES counterparts
(XVS, Endeavor, TAXUS Liberté, CYPHER; N=6 each). LDH values (in 485nm
absorbance) were normalized to MLV data.
Ex Vivo Comparisons of Stent Malapposition and Overlap
Devices were apposed to loop walls or under-expanded to a spectrum of stent:wall
separations - 0–60μm (malapposition threshold (MT), 150–210μm (intermediate), or 350–
400μm (severe) (Figure 1b–c; Supplemental Material). All stents were fixed within the loops
through 15 atm edge inflation. Some MLV stents were fully expanded to 15atm and
compared to thin BM (MLV), thick BM (TSV), or thin, drug-eluting (XVS) stents sub-
maximally expanded at MT (N=8 per group). Apposed MLV devices were compared to the
full spectrum of malapposition (N=8 per group). Other stents were overlapped and compared
to length-matched controls (Figure 1d). Three configurations were tested using 3.0×18mm
BMS (MLV and TSV) and DES (XVS) such that a 9mm overlapped region was formed,
33% of the total stented 27mm length (N=8 per overlap group). MLV (3.0×28mm, N=8
each) served as single, length-matched controls.
In Vivo Testing: Effect of Strut Thickness
Four Yorkshire swine (40–44kg) were maintained in accordance with Animal Welfare Act
and Institutional regulations. Pigs were anesthetized with inhaled isoflurane and local 2%
lidocaine. 6Fr femoral arterial access was obtained. Following heparinization, 3.0×12mm
stents were deployed into coronary arteries using standard techniques. Single stents (MLV
or TSV) were deployed into the left anterior descending (LAD), circumflex (Cx), or right
coronary artery (RCA) of each animal - 6 thin or thick stents in 12 vessels. Deployment was
staggered with 2 stents of each type in the 3 arterial positions. Animals were maintained on
normal pig chow diet and daily aspirin (600mg). Clopidogrel (300mg) was administered pre-
intervention. Following the procedure, pigs continued on aspirin (81mg) and clopidogrel
(75mg).
After 3 days, animals were euthanized. Stented segments were harvested (N=6 per stent
type), fixed in 10% neutral buffered formalin, dehydrated in ethanol, xylene cleared and
methyl methacrylate (MMA) resin embedded (Supplemental Material). Blocks were sawed
at proximal, mid and distal stent planes. 5μm thicknesses were sectioned and stained with
Hematoxylin/Eosin-Y and Verhoeff-vanGieson elastin stains. Luminal thrombus area was
quantified and fibrin content scored (0=Absent, 1=Light, 2=Moderate, 3=Heavy with spans
between struts) using Adobe Photoshop (Adobe Inc.). Mean values were averaged over the
stent length.
Computational Modeling
Flow perturbations induced by 81×81μm2 or 162×81μm2 struts (identical to MLV/TSV
platforms) were modeled within 3.0mm lumen at graded wall separation (0–320μm and the
centerline flow) with 1.5cm entrance and exit lengths. Separately, two 10 strut-long stents
with 5 overlapping struts were considered. Overlapping struts were congruent (aligned) or
non-congruent (off-set) – where struts lie precisely on top of each other or phase shifted to
various degrees as overlapping struts rest between underlying struts.
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A finite element-based non-Newtonian fluid dynamic module (COMSOL Inc.) solved the
Navier-Stokes equations in the arterial lumen (Supplemental Material). Steady Poiseuille
inlet conditions were characterized by typical coronary blood flow and symmetric vessel
characteristics (Reynolds number~242).15, 16 Zero-pressure outlet and no-slip blood-wall
interface boundary conditions were imposed. Delaunay triangulation set mesh generation
and the Direct (PARDISO) algorithm solved the linear equations. Mesh density increased
with successive simulation until less than 2% difference in the mean velocity in the distal
recirculation zone. This convergence was achieved after two successive mesh refinements
resulting in 35,648 triangular elements. Iterations for each simulation were performed until
the weighted Euclidean norm for the estimated relative error became less than 10−9.
Statistical Analysis
All experiments considered apposed MLV stents as a reference facilitating inter-group
comparisons. Ex vivo LDH data are thus provided as normalized ratios, expressed as mean ±
standard deviation. The Anderson-Darling test for normality was performed on all
observational groups (Supplemental Material). When sample normality was justified,
statistical comparisons between groups were performed using the unpaired Student’s t-test
assuming unequal variances. When normality could not be supported, the two-sample Mann-
Whitney test was employed. Provided p-values were derived from the Student’s t-test unless
otherwise indicated in the text. Experimental differences were statistically significant at
p<0.05.
Results
Impact of Basic Stent Features
Thicker stents were 49% more thrombogenic (1.49±0.20, p<0.001; Figure 2) and coated
stents less thrombogenic than matched MLV BMS (0.76±0.02 vs. 1.00±0.15, p=0.002;
Figure 2). These relationships held for stents of different designs. Clot mass remained
significantly reduced when all DES were pooled as a group and compared to BMS
(0.67±0.35 vs. 1.03±0.54, p=0.011 as determined by the Mann-Whitney test, Figures 3a–b).
Thrombogenicity within the various BMS designs correlated with strut thickness (0.88±0.38
for struts < 100μm vs. 1.44±0.65 for struts > 100μm, p=0.036 as determined by the Mann-
Whitney test, Figure 3c). These same results were observed in vivo. Radiographs of the
excised stented coronary arteries confirmed uniform deployment (Figure 4a–b). Thick
devices demonstrated significantly more thrombus after 3 days (Figure 4c–d) with 62%
more clot than with thinner versions (0.21±0.041 vs. 0.13±0.019mm2, p=0.004; Figure 4e).
Neointimal fibrin accumulated around thick struts more than thin (1.56±0.40 vs. 0.83±0.41,
p=0.016 via the Mann-Whitney test) commensurate with the location and extent of flow
stagnation and recirculation as determined computationally (3.6-fold downstream and 1.4-
fold upstream increase in recirculation area with increasing strut dimension; Figure 4f).
Impact of Suboptimal Stent Deployment: Malapposition
Thin and thick strut stents with 0–60μm wall separation were more thrombogenic than
apposed thin strut stents (1.58±0.17 and 1.64±0.17 vs. 1.00±0.27, p<0.001; Figure 5a). The
slightly malapposed thin-strut stents carried similar thrombotic risk to apposed thick-strut
stents (p=ns; Figure 2 and 5). DES coatings which reduced BMS thrombogenicity when
apposed continued to limit thrombogenicity malapposed (0.73±0.007, p=0.037). There was
no statistical difference between thin DES in apposed and malapposed configurations (p=ns,
Figures 2 and 5).
Intriguingly, malapposition could not explain thrombogenicity until the extent and pattern of
flow disruption associated with the strut and the wall was introduced. Clot mass was greatest
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at mild (1.58±0.17) and severe (1.30±0.10) malapposition, but less so at intermediate strut-
wall separation (0.85±0.17; Figure 5b). Strut-induced recirculation changed in size and
location depending on wall apposition (Figure 5c, d). Recirculation could appear adjacent to
the wall or stent; when the strut was close to the wall, these coincided. As strut-wall
separation increased, recirculation zones initially remained on the wall increasing in size.
With further displacement, they shifted downstream losing communication with the strut
itself. Eventually wall-contacting flow disturbances faded away all together. With greatest
wall separation, recirculation reemerged as strut-associated flow disruptions adjacent to and
on the downstream aspect of the strut, now apart from the wall and within the flow field.
Impact of Suboptimal Stent Deployment: Overlap
Overlapped BMS were more thrombogenic than single length-matched controls, and more
so for thick stents than thin (2.32±0.96 and 3.25±0.11 vs. 1.00±0.17, p<0.001 via the Mann-
Whitney test; Figure 6a). Moreover, overlapped thin DES (0.51±0.019) were less
thrombogenic than overlapped BMS (p<0.001) and even single BMS controls (p<0.001;
both via the Mann-Whitney test). Overlap increases the amount of stent material and
recirculation per unit length compared to non-overlapped portions, and more so for thicker
struts. Flow was restored between thin struts, and in non-congruent cases where overlap
allowed struts of upper stents to fall between struts of lower devices. When overlapping
stents were congruent with struts piled one on top of the other, recirculation increased and
was massive, spanning the entire overlapped inter-strut regions in thick strut cases (Figure
6b).
Discussion
Stent thrombosis (ST) is catastrophic and it is feared that addition of polymeric coatings and
drugs increases thrombotic risk.6, 17 We now show in a controlled model of early ST that
clinically relevant polymer-coated stents are consistently less, not more, thrombogenic than
matched bare-metal platforms especially in high risk interventions. More important to ST in
our models was the interaction of strut dimension and position relative to the vessel wall and
the potential alterations in flow and recirculation that are imposed by the implanted device.
In silico models allowed us to explore further a wide range of application scenarios and
device use combinations, demonstrating how thrombogenicity could be modified by
synergistic interactions between stent geometry and the local flow environment.
Effects of strut geometry
The importance of stent design and strut position relative to the vessel wall on
thrombogenicity is not unexpected,12 yet not fully supported by clinical data. Stent
implantation alters blood-exposed surfaces and luminal flow while creating a foreign
stimulus and nidus for clot.1, 2, 18 Doubling strut thickness nearly doubles foreign material
and increases flow separation, stagnation, and re-attachment (Figures 4f, 5f, 6b). Such flow
disruptions should enhance platelet deposition and thrombin and fibrin generation.19 In
ISAR-STEREO20–22 trials, thin-strut (50μm) stents elicited less restenosis than thick-strut
(140μm) BMS, and 96μm everolimus-eluting stents (XVS) were less thrombogenic than
164μm and 132μm paclitaxel-eluting devices (3% to 0.7%, p=0.003 and 1.1% to 0.3%,
p=0.004 respectively) in the SPIRIT IV17 and COMPARE23 trials. The latter studies
implicate strut dimension in ST but as they considered devices differing not only in
thickness but in delivered drug, elution kinetics, geometric design, material composition and
coating, they do not prove correlation. Indeed, when stents releasing rapamycin-like drugs
were compared clinically, thin platforms with rapid elution were not consistently better than
thicker, slow-release devices.24–26 Our work illuminates the impact of strut dimension on
ST as an isolated parameter and begins to explain these seemingly ambiguous and even
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contradictory clinical findings by incorporating other aspects of stent design and the context
in which the designs are deployed.
Material effects
Bare-metal thrombogenicity has long been recognized.12, 27 Metals may possess high
surface potentials that promote thrombus formation while corrosion can activate platelets
and pro-inflammatory pathways.28–31 Well-designed polymer coatings serve as corrosive
barriers and provide thromboresistance through modification of properties such as surface
potential, wettability, and roughness.30–32 Yet, polymer coatings are often perceived to be
less thromboresistant and less durable than metal, and remain long after drug release is
complete. That polymer coatings lowered thrombotic potential as compared to BMS in our
ST model, even in the face of challenging deployment, requires explanation.
In the pre-drug eluting era, we found hydrophobic polymer application to BMS reduced 14-
day thrombotic occlusion rate from 15% to 0% (p<0.01) in a rabbit iliac artery.12
Fluoropolymeric material and Dacron large artery bypass grafts offer clinical patency
similar to venous conduits early in their use.32, 33 Some analyses of clinical ST suggest
reduction in DES-related events as compared to BMS shortly after implantation1 and other
studies failed to show substantial differences between DES and BMS thrombosis rates.34
Despite possible reduction of early thrombogenicity with polymeric material, fear of DES
thrombosis is driven largely by late events where poor re-re-endothelialization, drug-
induced tissue factor expression, inflammation, polymer degradation and hypersensitivity,
and late acquired malapposition are observed.1, 2, 35 Richer definitions of biocompatibility
must therefore be invoked to explain clinical DES findings. Although polymer coatings can
be thromboresistant, thrombogenicity arises from the bioresponsiveness of time-variant,
environments and longitudinal ST risk is a balance of material, flow, and vascular
characteristics and responses. Considering the entire context is critical.
Effect of poor deployment
Strut malapposition and stent overlap are associated with ST.7 IVUS studies of older
generation stents reported stent-wall malapposition rates exceeding 20% and more recently
88% of stented lesions had at least one malapposed strut when examined with optical
coherence tomography (OCT).36 Malapposition can occur from inadequate deployment,
regression of interposed thrombus, or positive tissue remodeling inferior to the strut. Despite
efforts to reduce incomplete deployment, the asymmetric and calcific nature of
atherosclerotic lesions alone challenges stent positioning and some variation in placement is
inevitable. Though newer platforms, evolving implantation techniques37 and imaging
tools38, 39 reduce malapposition, recent meta-analyses show that DES as a group have more
late stent malapposition compared with BMS.35 When present, poor apposition increased ST
risk over six-fold.35
Many cases of ST have some malapposition, but most malapposition does not result in
thrombosis.35, 36 In our models malapposition alone could not account for thrombogenicity.
Clot mass increased most when struts were displaced a distance similar to the overall strut
height. As strut-wall separation grew, thrombogenicity fell and then increased again as struts
were displaced far into the flow field. Computational models validated that strut position in
the flow field significantly affects patterns of recirculation and stagnation. The shifting flow
patterns observed, coupled with respective thrombogenicities of the stent material and vessel
wall, may account for variable reports of ST. Large recirculating wall-contacting flows may
promote clot when the vessel wall is prothrombotic, as when necrotic, poorly re-
endothelialized, or rich in tissue-factor expression. As struts move further into the
freestream, flow recirculation between the strut and wall ceases, maximizing convective
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wall transport and then ST is the balance of blood interaction with the stent material and
flow alterations induced in the stream (Figure 5d).
As many as 30% of endovascular interventions receive multiple overlapping stents,
increasing the mass of foreign material, surface area for clot formation, and likelihood of
malapposition.9, 35, 40 Upper stents cannot be flush to the wall without excessive embedding
of the lower device. If lower devices are apposed, the upper stent will protrude significantly
into the flow field to an extent directly related to strut dimension. Our data confirm overlap-
associated ST risk, correlate strut protrusion with flow alteration and demonstrate the
exacerbation of effect with precise stent overlap alignment. When stents perfectly align,
struts lay precisely one on top of another and generate maximal flow disruption – when
alignment is out of phase, extent of flow separation is minimized. Real-life scenarios attain a
spectrum of strut positions relative to other overlapped struts, and here the importance of
dimensions emerge. As strut thickness increases, alignment can induce massive, global
recirculation zones in contrast to the local disruptions associated with thin struts. The
improvement provided by new generation, thinner devices may be accentuated in such
complex settings. In the SPIRIT IV trial, thinner devices performed better than thicker
platforms as a whole (HR 0.67) and twice as well in patients receiving multiple stents per
lesion (HR 0.33).17
Thrombogenicity in context
Williams and others increasingly insist that biological implants can never be inherently
biocompatible, but rather exhibit biocompatibility in specific scenarios.11 While the former
is a constitutive, intrinsic property of the implant, the latter is contextual and dependent on
application space. Emerging paradigms require that we define biological reactivity on the
basis of specific environments rather than material properties of the implants alone. Indeed,
platelet activation on stents of different materials was determined by the flow imposed and
drugs applied over the stents and to blood.13 We now extend this scheme to include
feedback effects wherein the implant defines its own context by imposing specific flow
disruptions. The size and position of the stents struts relative to the wall and each other
impact greatly the extent and position of recirculation and stagnation. This idea potentially
explains how minor degrees of malapposition can be insidiously problematic, and in contrast
how struts can cross the ostium of a branch vessel unnoticed. It also infers that there may
well be multiple modes of ST – those that arise by virtue of thrombopathology associated
with flow disruptions and the injured vessel wall, those that arise from flow alterations
around stent struts or from some combination of the two. With this in mind, endothelial
toxicity, tissue factor activation, altered healing and signaling take on added importance, and
issues related to stent deployment become intimately entwined with stent design.
Study Limitations
Ex vivo and computational models add insight into the factors impacting device thrombosis,
yet they are simplifications and their relevance to clinical settings must be considered. Flow
loops do not account for vascular wall response (for example reendothelialization or
inflammation) and non-compliant tubing cannot capture complex biomechanical strut-wall
interactions. Future flow models incorporating endothelial and smooth muscle cell linings
may offer even further insight. Still, the models allow methodical examination of highly
controlled environments not possible through animal or clinical testing alone. 2-D
simulations provide a glimpse of three-dimensional, time-varying flow fields, the full
characterization of which is beyond the manuscript’s scope, but whose elucidation should
contribute greatly to future understanding. Our ex vivo flow studies were performed using
porcine blood not exposed to antithrombotic agents to provide the greatest degree of control.
Drugs can reduce clot formation in our system but would cloud the central focus of these
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investigations. Moreover, assessment of thrombus was not fully blinded as quantifying clot
required stent handling and visualization. Finally, the LDH-based assay provides a sensitive,
but not specific marker of cellular material. Although LDH signal correlates with clot
weight, the contribution from fibrin formation versus platelet accumulation is not
characterized. Such mechanistic understanding could help tailor stent and environment-
specific drug therapies.
Conclusions
ST is a feared and fatal complication. Concerns that polymer-drug coatings are inherently
thrombogenic however must be reconsidered as early clotting is reduced by polymer-drug
coatings. Strut dimensions are associated with ST especially in high-risk deployment
configurations but inadequate deployment is not directly causal of ST or pathogenic until
one appreciates the flow disruption imposed by strut position. Flow tracking can bring
together seemingly disparate data regarding thrombosis and deployment, provide clinical
tools for optimal placement, direct choice of adjunctive medical therapy and drive future
stent design. Optimal designs are likely those that perform well despite inevitable variability
in deployment, and characterizing the flow-impact of device placement may more
appropriately define thrombotic risk.
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FIGURE 1.
Flow Loop, Reactive Sites, and Stent Configurations. (A) Closed flow loop with a 2.5cm
reactive site. Stents are deployed within reactive sites in desired conformations. Following a
run, the stented segment is excised and flushed. Adherent clot is assessed visually and
through LDH quantification. To determine the malapposition threshold, indigo dye was used
to detect stent-wall contact. (B) Proper stent deployment was modeled using apposed
configurations. (C) Incomplete stent deployment was modeled using under-deployed
configurations. (D) Overlapping stents were compared to length matched controls.
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FIGURE 2.
Relative ex vivo thrombogenicity between thin BMS (MLV), thick BMS (TSV), and DES
(XVS) in apposed configurations.
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FIGURE 3.
Ex vivo thrombogenicity among BMS and DES of different designs. (A) LDH thrombus
quantification and (B) visible clot as observed between pooled DES and BMS designs
showing a class effect. (C) LDH quantification in BMS designs grouped according to strut
thickness (< 100μm versus > 100μm strut).
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FIGURE 4.
In vivo thrombogenicity of thin (MLV) and thick (TSV) BMS in porcine coronary arteries
(n=6 each). (A, B) Radiographs of the excised arteries confirming full expansion of MLV
and TSV platforms respectively. (C, D) H&E staining of prepared sections derived from
MLV and TSV devices respectively 3 days post-implant. (E) Morphometric analysis of
adherent thrombus as assessed through luminal area measurement of MLV and TSV stented
sections. (F) Computational models depicting flow alterations surrounding apposed thick
(81μm × 162μm) and thin (81μm × 81μm) struts.
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FIGURE 5.
Ex vivo and computational assessment of malapposition cases. (A) Thrombogenicity of thin
BMS (MLV), thick BMS (TSV), and DES (XVS) when deployed at their malapposition
threshold (0–60μm displacement) as compared to apposed MLV controls. (B) Clot mass in
MLV platforms deployed in mild (0–60μm), intermediate (150–210μm), and severe (350–
400μm) malapposed configurations showing a variable response. (C) Single strut 2-D
simulations with varying displacements showing stent-wall recirculation zones which first
grow in size, shift downstream of the stent, lose stent communication, and then fade away
altogether. (D) Computed flow pattern with severe wall displacements (shown at the
centerline) depicting re-emergence of strut-associated recirculation. (E) Increased visual clot
burden observed with severe stent-wall displacement. Depending on the relative
thrombogenicities of the wall and the stent, the shifting strut-wall recirculation patterns may
help explain variability in malapposition-associated ST events.
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FIGURE 6.
Ex vivo and computational assessment of overlap cases. (A) Thrombogenicity of thin BMS
(MLV), thick BMS (TSV), and DES (XVS) when deployed in overlapped configurations as
compared with single, length-matched MLV controls. (B) 2-D flow simulations over thin
(81μm) and thick (162μm) overlapping stents in congruent or non-congruent configurations.
Depending on strut alignment, flow disruptions can be augmented in susceptible geometries
(as seen by the recirculation zone spanning the overlapped region in congruent, thick cases).
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